In the tumor microenvironment (Tumor Microenvironment, TME), Immune Checkpoint Inhibitors (ICIs) targeting PD-1 or PD-L1 enhance the body’s natural ability to eliminate cancer cells by disrupting the inhibitory receptor-ligand interaction. However, even so, critical trials indicate that the response rate for monotherapy is <50%, with a median Progr...